Optimi Health Corp (OTCQX:OPTHF) acquired thirty-three types of psilocybin and mushroom strains intended for cultivation.
The company will hold a set of twenty-four psychedelic and nine functional strains, adding them to one of the largest genetic banks in the sector. The psychedelic strains will be available for researchers licensed in Canada’s Special Acces Program and for Optimi’s analytical laboratory.
